Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03725592 · ClinicalTrials.gov registry record · NA
Strong Heart Water Study
A NA study of Arsenic Poisoning, sponsored by Johns Hopkins Bloomberg School of Public Health.
- Active
- Registry status
- NA
- Development phase
- 57
- Enrollment target
- 1
- Study location
NCT03725592: Active NA study of Arsenic Poisoning, sponsored by Johns Hopkins Bloomberg School of Public Health.
NCT03725592 is a NA study of Arsenic Poisoning that is active but no longer recruiting, run by Johns Hopkins Bloomberg School of Public Health. The registered enrollment target is 57 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03725592, a NA study of Arsenic Poisoning, is active but no longer recruiting, sponsored by Johns Hopkins Bloomberg School of Public Health.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 57 participants
- Enrollment target
- 1
- Study location
Study Summary
Develop and evaluate the effectiveness of multi-level participatory interventions in reducing arsenic exposure among American Indian (AI) communities from North and South Dakota who participated in the Strong Heart Study (SHS).
Primary Outcome
(1a) urine arsenic concentrations among household members (in parts per billion, µg/L)
Conditions Studied
Interventions
- OTHER Standard Treatment
- BEHAVIORAL Intensive Education
Study Locations (1)
Maryland
- Johns Hopkins Bloomberg School of Public Health, ICTR - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2018-07-02 |
| Est. Completion | 2026-05-04 |
| Phase | NA |
What the registry record for NCT03725592 still lists
NCT03725592 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Arsenic Poisoning appearing as the primary indexed condition, and to 2 interventions - of which Standard Treatment is the first listed.
NCT03725592 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT03725592 about?
NCT03725592 is a clinical study titled "Strong Heart Water Study". Develop and evaluate the effectiveness of multi-level participatory interventions in reducing arsenic exposure among American Indian (AI) communities from North and South Dakota who participated in the Strong Heart Study (SHS).
What is the current status of trial NCT03725592?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 57 participants. The study started on 2018-07-02. Estimated completion is 2026-05-04.
What conditions does trial NCT03725592 study?
This clinical trial studies the following conditions: Arsenic Poisoning.
What interventions are being tested in trial NCT03725592?
The interventions under investigation include: Standard Treatment (OTHER), Intensive Education (BEHAVIORAL).
Who is sponsoring clinical trial NCT03725592?
This trial is sponsored by Johns Hopkins Bloomberg School of Public Health, which has 187 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03725592 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arsenic Poisoning
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03725592's enrollment target sits among peer trials
57 1261st of 2000 higher than 739 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI